{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-25-000051","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.520088+00:00","generated_at":"2026-05-17T22:10:39.315868+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition","bullets":["Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).","Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.","GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.","Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-25-000051","json":"https://secwatch.observer/filing/0000012208-25-000051.json","markdown":"https://secwatch.observer/filing/0000012208-25-000051.md","text":"https://secwatch.observer/filing/0000012208-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/0000012208-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/bio-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:10:39.315868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}